Aim: DNA methyltransferases (DNMTs) are important drug targets for epigenetic therapy of cancer. Nowadays, non-nucleoside DNMT inhibitors are in development to address high toxicity of nucleoside analogs. However, these compounds still have low activity in cancer cells and mode of action of these compounds remains unclear. Materials & methods: In this work, we studied maleimide derivatives of RG108 by biochemical, structural and computational approaches to highlight their inhibition mechanism on DNMTs. Results: Findings demonstrated a correlation between cytotoxicity on mesothelioma cells of these compounds and their inhibitory potency against DNMTs. Noncovalent and covalent docking studies, supported by crystallographic (apo structure of M.HhaI) and differential scanning fluorimetry assays, provided detailed insights into their mode of action and revealed essential residues for the stabilization of such compounds inside DNMTs. </inline-graphic.
- apoenzyme crystal structure
- DNA methylation
- DNA methyltransferases
- Michael acceptor
FingerprintDive into the research topics of 'Inhibition studies of DNA methyltransferases by maleimide derivatives of RG108 as non-nucleoside inhibitors'. Together they form a unique fingerprint.
Technological Platform Physical Chemistry and characterization
Facility/equipment: Technological Platform